These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25297629)

  • 21. Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer.
    Penny SA; Abelin JG; Malaker SA; Myers PT; Saeed AZ; Steadman LG; Bai DL; Ward ST; Shabanowitz J; Hunt DF; Cobbold M
    Front Immunol; 2021; 12():723566. PubMed ID: 34504498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.
    O'Neil BH; Kawakami Y; Restifo NP; Bennink JR; Yewdell JW; Rosenberg SA
    J Immunol; 1993 Aug; 151(3):1410-8. PubMed ID: 8335937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
    Ebstein F; Sapede C; Royer PJ; Marcq M; Ligeza-Poisson C; Barbieux I; Cellerin L; Dabouis G; Grégoire M
    Am J Respir Crit Care Med; 2004 Jun; 169(12):1322-30. PubMed ID: 15070823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.
    Unger WW; Pearson T; Abreu JR; Laban S; van der Slik AR; der Kracht SM; Kester MG; Serreze DV; Shultz LD; Griffioen M; Drijfhout JW; Greiner DL; Roep BO
    PLoS One; 2012; 7(11):e49213. PubMed ID: 23155466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the human CD4(+) T-cell repertoire specific for major histocompatibility class I-restricted antigens.
    Legoux F; Gautreau L; Hesnard L; Leger A; Moyon M; Devilder MC; Bonneville M; Saulquin X
    Eur J Immunol; 2013 Dec; 43(12):3244-53. PubMed ID: 23963968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
    Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
    Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
    Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
    J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
    Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
    Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
    Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
    Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
    Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
    J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
    Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
    J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.